These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34239768)

  • 1. Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives.
    Siafaka P; Ipekci E; Caglar EŞ; Ustundag Okur N; Buyukkayhan D
    Medeni Med J; 2021; 36(2):152-162. PubMed ID: 34239768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric drug formulations: a review of challenges and progress.
    Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
    Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children.
    Bhatt-Mehta V; Hammoud H; Amidon GL
    Eur J Pharm Sci; 2020 Sep; 152():105437. PubMed ID: 32598914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Providing Suitable Pediatric Formulations for Canadian Children: A Call for Action.
    Litalien C; Autmizguine J; Carli A; Giroux D; Lebel D; Leclerc JM; Théorêt Y; Gilpin A; Bérubé S
    Can J Hosp Pharm; 2020; 73(4):247-256. PubMed ID: 33100356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
    Strickley RG
    J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
    Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
    Thabet Y; Klingmann V; Breitkreutz J
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
    Kersten E; Barry A; Klein S
    Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
    Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
    Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric formulations--getting to the heart of the problem.
    Standing JF; Tuleu C
    Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.
    Sosnik A; Seremeta KP; Imperiale JC; Chiappetta DA
    Expert Opin Drug Deliv; 2012 Mar; 9(3):303-23. PubMed ID: 22257003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Better medicines for children' within the Integrated Management of Childhood Illness framework: a qualitative inquiry in Uganda.
    Nsabagasani X; Ogwal-Okeng J; Hansen EH; Mbonye A; Muyinda H; Ssengooba F
    J Pharm Policy Pract; 2016; 9():22. PubMed ID: 27280024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues impacting therapeutic outcomes in pediatric patients: an overview.
    Kalra A; Goindi S
    Curr Pediatr Rev; 2014; 10(3):184-93. PubMed ID: 25088338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.
    van Riet-Nales DA; Schobben AF; Egberts TC; Rademaker CM
    Clin Ther; 2010 May; 32(5):924-38. PubMed ID: 20685501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets: Summary of September 2019 EuPFI workshop.
    Harris D; Hermans E; Klein S; Wagner-Hattler L; Walsh J
    Eur J Pharm Biopharm; 2020 Aug; 153():222-225. PubMed ID: 32580052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings.
    Weidle PJ; Abrams EJ; Gvetadze R; Rivadeneira E; Kline MW
    Pediatr Infect Dis J; 2006 Jan; 25(1):59-64. PubMed ID: 16395105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.